Adjuvant Therapy News and Research

RSS

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.

Policy review demands better quality of life data in cancer clinical trials

A new policy review from Common Sense Oncology (CSO) and the European Organisation for Research and Treatment of Cancer (EORTC) calls for quality of life data to play a more central role in clinical trials evaluating adjuvant cancer treatments.

1 Oct 2026

New integrated framework advances precision surgery for liver cancer

Hepatocellular carcinoma is the sixth most common malignancy and the third leading cause of cancer-related death globally.

9 Sep 2026

Post-surgery immunotherapy may not benefit specific lung cancer patients

A new real-world observational study has found that adding adjuvant immunotherapy after surgery does not significantly improve survival outcomes in patients with resectable non-small cell lung cancer (NSCLC) who have already achieved a pathological complete response (pCR) following neoadjuvant chemoimmunotherapy.

2 Sep 2026

Alliance highlights the importance of clinical research on World Breast Cancer Research Day

This World Breast Cancer Research Day, the Alliance for Clinical Trials in Oncology is highlighting the importance of clinical research in advancing better treatments and improving early detection to ultimately help prevent and cure breast cancer.

18 Aug 2026

RNA-based therapeutic strategy targets brain pathway behind cancer-associated cachexia

A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away.

2 Aug 2026

Study identifies simvastatin as promising adjuvant for periodontitis treatment

Porphyromonas gingivalis can evade antibiotics by invading host cells, contributing to recurrent periodontitis and persistent tissue damage.

26 Jul 2026

New bacterial control strategy helps revive failing last-line antibiotics

Antimicrobial resistance is one of the world's most alarming public health challenges, because the multidrug-resistant (MDR) gram-negative bacteria increasingly render even last-line antibiotics ineffective, leading to substantially higher mortality rates.

23 Jul 2026

Integrating gene signatures and multi omics improves liver cancer treatment

Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers.

14 Jul 2026

Blood test may predict which colorectal cancer patients benefit from chemotherapy

A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.

3 Jul 2026

FDA accepts immunotherapy drug for review in colon cancer treatment

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

11 Jun 2026

Molecular profiling initiative seeks to uncover late breast cancer recurrence mysteries

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), in collaboration with the SWOG Cancer Research Network (SWOG), has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials.

19 May 2026

EV-RNAs show promise for IBD diagnosis and treatment

A research team led by Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, has published a comprehensive review in ExRNA that sorts out the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD).

10 Apr 2026

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

Largest trial of adjuvant pembrolizumab in Merkel cell carcinoma reports key benefit

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial.

21 Oct 2025

Exercise improves cancer outcomes by shaping the gut microbiome

A new study from the University of Pittsburgh shows for the first time how exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome.

9 Jul 2025

Blood test for tumor DNA may predict melanoma recurrence

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

15 Apr 2025

ASCOLT trial explores aspirin’s role in preventing colorectal cancer recurrence

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer has concluded.

17 Mar 2025

Light-activated therapy reduces antibiotic resistance in Staphylococcus aureus

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, enhancing treatment effectiveness.

11 Feb 2025

New research shines light on position-specific hallmarks of cancer

A team led by the Cancer Immunogenomics group at the Josep Carreras Leukaemia Research Institute, the Computational Biology group at the Barcelona Supercomputing Center and the Germans Trias i Pujol Research Institute shows, for the first time, that within a tumor, the expression of the different hallmarks of cancer is not cell-specific, but rather position-specific.

30 Jan 2025